Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Apr;3(2):151-6.
doi: 10.1016/j.molonc.2009.01.001. Epub 2009 Feb 7.

Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease

Affiliations
Review

Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease

Amir A Jazaeri. Mol Oncol. 2009 Apr.

Abstract

BRCA1 and BRCA2 germline mutations account for the majority of hereditary ovarian cancers and comprise 10% of total cases. Ovarian cancers arising from these mutations exhibit both overlapping and distinct clinical and molecular features. The expression profiles of sporadic ovarian cancers show similarities to those of BRCA1 and BRCA2-related tumors suggesting that BRCA-related pathways may be involved in their development as well. The purpose of this review is to consider the available data on ovarian cancers in the context of other investigations of BRCA-related transcriptional alterations, and highlight areas for future research.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall expression differences between BRCA1‐linked, BRCA2‐linked, and sporadic ovarian epithelial cancers. (A) Unsupervised multidimensional scaling model based on the overall gene expression in BRCA1‐linked, BRCA2‐linked, and sporadic tumors. (B) The magnitude of differences in gene expression between various tumor groups as determined by the number of genes differentially expressed among the tumor groups when the uniform statistical cutoff P<0.0001 is applied. Figure reproduced with permission from Jazaeri et al. (2002).
Figure 2
Figure 2
BRCA1 and BRCA2‐discriminating genes also segregate sporadic ovarian cancers into two groups. (A) Hierarchical clustering of 110 non‐redundant genes with statistically significant differential expression between BRCA1‐linked (B1) and BRCA2‐linked (B2) tumors (modified F test, P<0.0001). The red and green intensities represent standard normal deviation (Z score) values from each gene's mean expression level (represented as black) across all 61 tumor samples. (B) Hierarchical clustering of sporadic and BRCA‐linked tumor samples based on the expression pattern of the 110 BRCA‐discriminating genes. The two major clusters correspond to BRCA1‐like (blue) and BRCA2‐like (orange) patterns of gene expression. B=BRCA1‐linked tumor; B2=BRCA2‐linked tumor; C=sporadic tumors. Tumor histology for each sample is indicated below the sample label as follows: S=serous; A=adenocarcinoma not otherwise specified; E=endometrioid; C=clear cell; M=mixed features. (C) Hierarchical clustering of sporadic samples in the absence of BRCA‐linked tumors. Note the maintenance of cluster integrity. Each sporadic sample is colored according to its cluster identity in B. The median age in years is shown for each major cluster. Figure reproduced with permission from Jazaeri et al. (2002).

Similar articles

Cited by

References

    1. Antoniou, A.C. , Pharoah, P.D. , Narod, S. , Risch, H.A. , Eyfjord, J.E. , Hopper, J.L. , Olsson, H. , Johannsson, O. , Borg, A. , Pasini, B. , Radice, P. , Manoukian, S. , Eccles, D.M. , Tang, N. , Olah, E. , Anton-Culver, H. , Warner, E. , Lubinski, J. , Gronwald, J. , Gorski, B. , Tulinius, H. , Thorlacius, S. , Eerola, H. , Nevanlinna, H. , Syrjakoski, K. , Kallioniemi, O.P. , Thompson, D. , Evans, C. , Peto, J. , Lalloo, F. , Evans, D.G. , Easton, D.F. , 2005. Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J. Med. Genet.. 42, 602–603. - PMC - PubMed
    1. Boyd, J. , Sonoda, Y. , Federici, M.G. , Bogomolniy, F. , Rhei, E. , Maresco, D.L. , Saigo, P.E. , Almadrones, L.A. , Barakat, R.R. , Brown, C.L. , Chi, D.S. , Curtin, J.P. , Poynor, E.A. , Hoskins, W.J. , 2000. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA. 283, 2260–2265. - PubMed
    1. Brown, L.A. , Irving, J. , Parker, R. , Kim, H. , Press, J.Z. , Longacre, T.A. , Chia, S. , Magliocco, A. , Makretsov, N. , Gilks, B. , Pollack, J. , Huntsman, D. , 2006. Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Gynecol. Oncol. 100, 264–270. - PubMed
    1. Bryant, H.E. , Schultz, N. , Thomas, H.D. , Parker, K.M. , Flower, D. , Lopez, E. , Kyle, S. , Meuth, M. , Curtin, N.J. , Helleday, T. , 2005. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 434, 913–917. - PubMed
    1. Buller, R.E. , Shahin, M.S. , Geisler, J.P. , Zogg, M. , De Young, B.R. , Davis, C.S. , 2002. Failure of BRCA1 dysfunction to alter ovarian cancer survival. Clin. Cancer Res.. 8, 1196–1202. - PubMed